| Cash flow (USD) | Q1 2026 ended Mar 31, 2026 | Q4 2025 ended Dec 31, 2025 | Q3 2025 ended Sep 30, 2025 | Q2 2025 ended Jun 30, 2025 | Q1 2025 ended Mar 31, 2025 | Q4 2024 ended Dec 31, 2024 | Q3 2024 ended Sep 30, 2024 | Q2 2024 ended Jun 30, 2024 |
|---|---|---|---|---|---|---|---|---|
| Net income | 1.08B | 1.78B | 1.64B | 1.78B | 1.32B | 9.23B | 1.65B | 1.30B |
| Depreciation and amortization | 381.00M | 370.00M | 371.00M | 357.00M | 336.00M | 342.00M | 331.00M | 334.00M |
| Stock-based compensation | 317.00M | 113.00M | 120.00M | 142.00M | 289.00M | 111.00M | 117.00M | 141.00M |
| Cash from operations | 1.31B | 3.31B | 2.79B | 2.05B | 1.42B | 2.87B | 2.71B | 1.96B |
| Capital expenditure | -399.00M | -689.00M | -496.00M | -502.00M | -484.00M | -720.00M | -556.00M | -533.00M |
| Free cash flow | 916.00M | 2.63B | 2.29B | 1.54B | 933.00M | 2.15B | 2.15B | 1.43B |
| Cash from investing | -20.32B | -913.00M | -457.00M | -582.00M | -470.00M | -866.00M | -594.00M | -453.00M |
| Dividends paid | -1.10B | -1.03B | -1.03B | -1.03B | -1.03B | -958.00M | -960.00M | -961.00M |
| Share buybacks | -180.00M | -302.00M | -305.00M | -6.00M | -280.00M | -315.00M | -751.00M | -3.00M |
| Net debt issued | 18.44B | -501.00M | 1.00M | -1.00B | -1.00M | 203.00M | ||
| Cash from financing | 17.31B | -1.40B | -1.76B | -1.10B | -2.06B | -1.86B | -1.58B | -791.00M |
| Net change in cash | -1.72B | 1.01B | 560.00M | 419.00M | -1.08B | 58.00M | 571.00M | 703.00M |
From Abbott Laboratories's 10-K and 10-Q filings with the SEC. Fourth quarters, and quarters where the company only reported year-to-date totals, are worked out by subtracting the earlier quarters. Fiscal years are the company's own, so they may not match the calendar. A blank cell means the company did not report that line. New to this? Read cash flow or reading a 10-K.
Revenue, earnings, margins and balance sheet trends drawn by TradingView from its own data, so figures can differ slightly from the SEC table above.